Dana-Farber Cancer Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Dana-Farber Cancer Institute sits in the top decile of US sponsors by registered trial count (#42 of 15,742 sponsors by registered trial count).
Dana-Farber Cancer Institute: 781 sponsored US clinical trials, 112 recruiting.
Dana-Farber Cancer Institute sponsors 781 registered US clinical trials on ClinicalTrials.gov, 112 of them currently recruiting, and 449 completed. 15 of these trials are in Phase 3-4 (later-stage) and 492 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 53 trials.
Top-decile sponsor footprint
Dana-Farber Cancer Institute ranks in the top decile of sponsors by registered trial count (#42 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
449 of 537 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
781 total, page 11 of 16
Breast MRI for Newly Diagnosed Breast Cancer:Impact on Re-excision Lumpectomy
NCT01568346
Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL
NCT01465334
Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL
NCT01523977
Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia
NCT01470196
RPFNA Assessment of Exercise Effect in Breast Cancer
NCT01961128
Image-Guided Gynecologic Brachytherapy
NCT01399658
Promoting Organizational Capacity to Implement Cancer Control Programs Among Latino Churches
NCT01740219
Dasatinib in Advanced Squamous Cell Lung Cancer
NCT01491633
STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma
NCT01551693
A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors
NCT02133625
Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study
NCT01221753
Methylphenidate for Cancer-Related Fatigue
NCT01164956
The Myelodysplasia Transplantation-Associated Outcomes (MDS-TAO) Study
NCT02390414
Socialization of Adult Men With Congenital Hemophilia A or B
NCT01510418
Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors
NCT01323920
Exercise and Metformin in Colorectal and Breast Cancer Survivors
NCT01340300
Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization in Multiple Myeloma Patients Undergoing ASCT
NCT01286675
Pilot Study for Young Women's Intervention
NCT01647594
Comparison of Creatinine Clearance Calculation for Estimation of GFR in Patients Receiving HD Methotrexate
NCT01319591
CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
NCT01191697
Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer
NCT01184326
Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer
NCT01273805
Amgen 386 for Recurrent Glioblastoma
NCT01290263
Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer
NCT01222572
Trastuzumab and Vinorelbine in Advanced Breast Cancer
NCT01185509
SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT)
NCT01402687
Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro
NCT01472627
Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease
NCT01226420
STA-9090(Ganetespib) in Metastatic Ocular Melanoma
NCT01200238
Impact of Adnexal Involvement of the Severity and Prognosis of Chronic Graft-versus-Host Disease
NCT01221766
NIR-Guided Sentinel Lymph Node Mapping in Melanoma
NCT01121718
Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer
NCT00925652
FLT PET/CT for Staging, Target Definition and Assessment of Response to Therapy in Patients With Esophageal Cancer
NCT01243619
Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer
NCT01253369
Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
NCT01085201
Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
NCT01125293
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
NCT01024387
Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT01066663
Panobinostat (LBH589) in Patients With Metastatic Melanoma
NCT01065467
RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
NCT01058655
RAD001 With Weekly Cisplatin and Radiation Therapy in Patients With Locally Advanced Head and Neck Cancer
NCT01058408
Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer
NCT00889187
Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases
NCT01004172
Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia
NCT00976248
Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease
NCT01000155
Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer
NCT00953576
Cosmetic Result/Toxicity in Post-Mastectomy Immediate Reconstruction Expander+RT
NCT01664091
RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
NCT00936858
Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer
NCT00911820
LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia
NCT00936611
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 181 |
| Phase 2 | 311 |
| Phase 3 | 14 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Dana-Farber Cancer Institute pipeline
112 recruiting of 781 indexed (14% open); 449 completed (57%).
Phase mix: 15 late (III/IV) vs 492 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (53 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Dana-Farber Cancer Institute: open-pipeline peers nationwide
Peers matched on 781 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Dana-Farber Cancer Institute sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 781 trials (± recruiting share)
- University of California, San Diego · 775 trials · 18% recruiting
- University of Chicago · 796 trials · 20% recruiting
- Medical University of South Carolina · 755 trials · 19% recruiting
- University of Utah · 818 trials · 17% recruiting
Sponsors near 14% open enrollment (± trial volume)
- The Cleveland Clinic · 14% recruiting · 688 trials
- Academic and Community Cancer Research United · 14% recruiting · 42 trials
- Adaptive Biotechnologies · 14% recruiting · 7 trials
- AgelessRx · 14% recruiting · 7 trials
Related
What to do with this Dana-Farber Cancer Institute page
781 registered trials is a research-attention snapshot, not an endorsement of Dana-Farber Cancer Institute or any single study.
- 112 of Dana-Farber Cancer Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Dana-Farber Cancer Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Dana-Farber Cancer Institute pipeline card: 781 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.